CPMEA Releases 2026 Pre-Budget Submission

CPMEA has submitted its recommendations for Canada’s 2026 Budget, calling for targeted federal action to strengthen domestic pharmaceutical manufacturing and protect Canada’s pharmaceutical sovereignty.

Canada’s biomanufacturing sector produces more than $16 billion in output annually, employs approximately 33,000 Canadians and exported almost $12 billion to the United States in 2024. At the same time, CPMEA’s submission highlights growing pressures on Canadian manufacturers from U.S. tariffs, reshoring policies and international competition for pharmaceutical investment.

To help Canada remain competitive and preserve domestic production capacity, CPMEA’s recommendations focus on four key areas: competitive tax policy, priority regulatory review for Canadian producers, Canada-first procurement, and the inclusion of domestic medicine production in Canada’s defence strategy.

The submission includes proposals for manufacturing and onshoring tax incentives, improvements to SR&ED support, additional resources for Health Canada, procurement policies that support Canadian-made medicines, and investment in domestic capacity for essential medicines and medical countermeasures.

Together, these measures are intended to help retain pharmaceutical investment, manufacturing capacity and skilled jobs in Canada while strengthening the country’s health, economic and national security.

Read CPMEA’s full 2026 Pre-Budget Submission on our Resources page.